This page contains a Flash digital edition of a book.
“WHO’S A STINKY, STUPID, BABY, BEDWETTER?”


Bedwetting can be a distressing condition. Children may suffer low self esteem, anxiety, depression and become withdrawn.1-3


And those wetting the bed twice a week or


more are more likely to continue throughout childhood into adolescence.4,5


It is important that children who wet the bed twice a week or more are identified early, and treated quickly and effectively.4,5


Prescribing Information: DesmoMelt® 120 and 240 micrograms oral lyophilisate; Desmotabs® 0.2mg. Please consult the full Summaries of Product Characteristics before prescribing. Name of Product: DesmoMelt 120 micrograms oral lyophilisate; DesmoMelt 240 micrograms oral lyophilisate; Desmotabs 0.2mg; Composition: DesmoMelt: 120 or 240 micrograms of desmopressin (as acetate). Desmotabs: 0.2mg desmopressin acetate. Indications: Treatment of primary nocturnal enuresis (5 to 65 years of age). Dosage: Children and adults (5–65 years of age) with normal urine concentrating ability: DesmoMelt: Initial dose of 120 micrograms sublingually at bedtime and only if needed should the dose be increased to 240 micrograms sublingually. Desmotabs: Initial dose of one tablet (0.2mg) at bedtime and only if needed should the dose be increased to two tablets (a total of 0.4mg). Fluid restriction should be observed. The need for continued treatment should be reassessed after 3 months by means of a period of at least 1 week without desmopressin. Contraindications: Cardiac insufficiency and other conditions requiring treatment with diuretics, moderate and severe renal insufficiency. DesmoMelt and Desmotabs should only be used in patients with normal blood pressure and they should not be used in patients over the age of 65. Exclude diagnosis of psychogenic polydipsia or alcohol abuse. Special Warnings and Precautions: Take care in patients with reduced renal function and/or cardiovascular disease or cystic fibrosis. Fluid intake must be limited to a minimum from 1 hour before until 8 hours after administration.


120 mcg and 240 mcg oral lyophilisate desmopressin (as acetate)


DesmoMelt can be used from 5 years of age and is preferred to tablets, especially by younger children.6 MELT AWAY THE MISERY OF BEDWETTING


Care should be taken to avoid ingesting water while swimming. Treatment with desmopressin should be interrupted during an episode of vomiting and/or diarrhoea until their fluid balance is once again normal. Precautions to prevent fluid overload must be taken in: illnesses characterized by fluid and/or electrolyte imbalance; patients at risk for increased intracranial pressure. Side Effects: Headache, stomach pain and nausea. Isolated cases of allergic skin reactions and more severe general allergic reactions. Very rare cases of emotional disturbances in children. Treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with or without accompanying warning symptoms of headache, nausea/ vomiting, decreased serum sodium, weight gain and in serious cases convulsions. Please consult the full Summaries of Product Characteristics for further information about side effects. Basic NHS Prices: DesmoMelt: Carton containing 30 oral lyophilisates in blister strips. 30 x 120 micrograms £30.34. 30 x 240 micrograms £60.68. Desmotabs: Polyethylene bottle containing 30 tablets. £29.43. Marketing Authorisation Number: DesmoMelt: 120 micrograms 03194/0094. 240 micrograms 03194/0095. Desmotabs: 03194/0046. Marketing Authorisation Holder: Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS. Legal Category: Date of Preparation of Prescribing Information: May 2011. All trademarks registered to Ferring. References: 1. Hägglöf B et al. Scand J Urol Nephrol 1996;


POM


183:79-82. 2. Warzak WJ. Clinical Pediatrics 1993; 38-40. 3. Hjälmås K. Acta Paediatr 1997; 86: 919-22. 4. Yeung CK et al. BJU Int 2006; 97: 1069-1073. 5. Butler RJ & Heron J. Scan J Urol Neph 2008; 42: 257-64. 6. Lottman H et al. Int J Clin Pract 2007; 61(9): 1454-1460.


Further information is available from: Ferring Pharmaceuticals Ltd., Drayton Hall, Church Road, West Drayton, UB7 7PS. Telephone: 0844 9310050.


*DesmoMelt and Desmotabs are trademarks of Ferring BV.


Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Medical Information, Ferring Pharmaceuticals Ltd. Tel: 0844 9310050. Email: medical@ferring.com


www.urinecontrol.co.uk www.doctors.net.uk/nocturnal_enuresis


Date of preparation: January 2012. DN/389/2011/UKk


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84